Foghorn Therapeutics (FHTX) Retained Earnings (2020 - 2025)
Historic Retained Earnings for Foghorn Therapeutics (FHTX) over the last 6 years, with Q3 2025 value amounting to -$610.8 million.
- Foghorn Therapeutics' Retained Earnings fell 1338.46% to -$610.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$610.8 million, marking a year-over-year decrease of 1338.46%. This contributed to the annual value of -$558.2 million for FY2024, which is 1836.87% down from last year.
- Foghorn Therapeutics' Retained Earnings amounted to -$610.8 million in Q3 2025, which was down 1338.46% from -$595.0 million recorded in Q2 2025.
- Foghorn Therapeutics' Retained Earnings' 5-year high stood at -$185.9 million during Q1 2021, with a 5-year trough of -$610.8 million in Q3 2025.
- For the 5-year period, Foghorn Therapeutics' Retained Earnings averaged around -$414.4 million, with its median value being -$433.1 million (2023).
- Its Retained Earnings has fluctuated over the past 5 years, first tumbled by 6536.52% in 2021, then tumbled by 1338.46% in 2025.
- Foghorn Therapeutics' Retained Earnings (Quarter) stood at -$264.3 million in 2021, then tumbled by 41.2% to -$373.1 million in 2022, then fell by 26.38% to -$471.6 million in 2023, then fell by 18.37% to -$558.2 million in 2024, then decreased by 9.43% to -$610.8 million in 2025.
- Its last three reported values are -$610.8 million in Q3 2025, -$595.0 million for Q2 2025, and -$577.0 million during Q1 2025.